BioCentury | Sep 12, 2011
Company News

Evec, Astellas deal

...exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec...
...receive up to ¥13 billion ($169 million) in milestones, plus royalties. Details were not disclosed. Evec Inc....
BioCentury | Sep 7, 2011
Company News

Evec, Astellas in infectious disease deal

...exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec...
Items per page:
1 - 2 of 2
BioCentury | Sep 12, 2011
Company News

Evec, Astellas deal

...exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec...
...receive up to ¥13 billion ($169 million) in milestones, plus royalties. Details were not disclosed. Evec Inc....
BioCentury | Sep 7, 2011
Company News

Evec, Astellas in infectious disease deal

...exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec...
Items per page:
1 - 2 of 2